Learning from biology: Synthetic lipoproteins for drug delivery

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 7, Issue 3, 2015, Pages 298-314

  Huang, Huang ^a,b   Cruz, William ^a,b   Chen, Juan ^b   Zheng, Gang ^b,c  

^a DLVR Therapeutics Inc   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; CONTROLLED DRUG DELIVERY; DISEASES; LIPIDS; NANOPARTICLES; PHOTOSENSITIZERS; TARGETED DRUG DELIVERY;

BIOLOGICAL FUNCTIONS; CIRCULATION HALF-LIFES; CLINICAL TRANSLATION; FUTURE PERSPECTIVES; LIPOPROTEIN RECEPTORS; LOW DENSITY LIPOPROTEIN RECEPTORS; NANOPARTICLE SYSTEMS; PATHOLOGICAL CONDITIONS;

LIPOPROTEINS;

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; APOLIPOPROTEIN; BACTERIOCHLORIN; CURCUMIN; CYTOTOXIC AGENT; GADOLINIUM PENTETATE; GOLD NANOPARTICLE; HIGH DENSITY LIPOPROTEIN RECEPTOR; HYPERICIN; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOPARTICLE; PACLITAXEL; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC AGENT; QUANTUM DOT; RAPAMYCIN; RECOMBINANT APOLIPOPROTEIN; RECOMBINANT PROTEIN; SIMVASTATIN; SMALL INTERFERING RNA; SYNTHETIC HIGH DENSITY LIPOPROTEIN; SYNTHETIC LIPOPROTEIN; SYNTHETIC LOW DENSITY LIPOPROTEIN; SYNTHETIC PEPTIDE; TANSHINONE IIA; UNCLASSIFIED DRUG; BIOMIMETIC MATERIAL; CONTRAST MEDIUM; NANOCAPSULE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOCOMPATIBILITY; BIOMIMETICS; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MOLECULAR BIOLOGY; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; TRANSLATIONAL RESEARCH; TUMOR CELL LINE; ANIMAL; CHEMISTRY; CRYSTALLIZATION; MOLECULARLY TARGETED THERAPY; PROCEDURES; SYNTHESIS;

ANIMALS; BIOMIMETIC MATERIALS; CONTRAST MEDIA; CRYSTALLIZATION; HUMANS; LIPOPROTEINS; MOLECULAR TARGETED THERAPY; NANOCAPSULES;

EID: 84927138444     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1308     Document Type: Review

References (141)

1. De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 2008, 3:133-149.
2. Dobrovolskaia MA, Mcneil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2:469-478.
3. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, Van Rooijen N, Corstens FH, Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 2001, 298:607-612
4. Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu T, Tan W. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine (Lond) 2012, 7:1253-1271.
5. Sabnis N, Lacko AG. Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Deliv 2012, 3:599-608.
6. Zhang L, Song J, Cavigiolio G, Ishida BY, Zhang S, Kane JP, Weisgraber KH, Oda MN, Rye KA, Pownall HJ, et al. Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy. J Lipid Res 2011, 52:175-184.
7. Silva RA, Huang R, Morris J, Fang J, Gracheva EO, Ren G, Kontush A, Jerome WG, Rye KA, Davidson WS. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci U S A 2008, 105:12176-12181.
8. Teerlink T, Scheffer PG, Bakker SJ, Heine RJ. Combined data from LDL composition and size measurement are compatible with a discoid particle shape. J Lipid Res 2004, 45:954-966.
9. Ginsberg HN. Lipoprotein physiology. Endocrinol Metab Clin North Am 1998, 27:503-519.
10. Crook MA. Clinical Biochemistry and Metabolic Medicine, vol. 8. London: Hodder Arnold; 2012.
11. Lin Q, Chen J, Zhang Z, Zheng G. Lipid-based nanoparticles in the systemic delivery of siRNA. Nanomedicine (Lond) 2014, 9:105-120.
12. Wakil SJ. Lipid Metabolism. New York: Academic Press; 1970.
13. Faergeman O, Havel RJ. Metabolism of cholesteryl esters of rat very low density lipoproteins. J Clin Invest 1975, 55:1210-1218.
14. Eisenberg S, Windmueller HG, Levy RI. Metabolic fate of rat and human lipoprotein apoproteins in the rat. J Lipid Res 1973, 14:446-458.
15. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004, 126:16316-16317.
16. Davidson MH. Apolipoprotein measurements: Is more widespread use clinically indicated? Clin Cardiol 2009, 32:482-486.
17. Barter P, Kastelein J, Nunn A, Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003, 168:195-211.
18. Mcgrowder D, Riley C, Morrison EY, Gordon L. The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol 2011, 2011:496925.
19. Mowat BF, Skinner ER, Wilson HM, Leng GC, Fowkes FG, Horrobin D. Alterations in plasma lipids, lipoproteins and high density lipoprotein subfractions in peripheral arterial disease. Atherosclerosis 1997, 131:161-166.
20. Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999, 68:523-558.
21. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, Part II. Circulation 2001, 104:2498-2502.
22. Lacko AG, Nair M, Prokai L, Mcconathy WJ. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv 2007, 4:665-675.
23. Lin Q, Jin CS, Huang H, Ding L, Zhang Z, Chen J, Zheng G. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. Small 2014, 10:3072-3082.
24. Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, Cao W, Lo PC, Yang M, Tsao MS, et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 2010, 6:430-437.
25. Pluen A, Boucher Y, Ramanujan S, Mckee TD, Gohongi T, Di Tomaso E, Brown EB, Izumi Y, Campbell RB, Berk DA, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:4628-4633.
26. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
27. Danilo C, Gutierrez-Pajares JL, Mainieri MA, Mercier I, Lisanti MP, Frank PG. Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res 2013, 15:R87.
28. Twiddy AL, Cox ME, Wasan KM. Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cells. Prostate 2012, 72:955-965.
29. Narasimhan K, Pillay S, Bin Ahmad NR, Bikadi Z, Hazai E, Yan L, Kolatkar PR, Pervushin K, Jauch R. Identification of a polyoxometalate inhibitor of the DNA binding activity of Sox2. ACS Chem Biol 2011, 6:573-581.
30. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 1978, 52:1099-1114.
31. Chen Y, Hughes-Fulford M. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int J Cancer 2001, 91:41-45.
32. Qiu Y, Liu S, Chen HT, Yu CH, Teng XD, Yao HT, Xu GQ. Upregulation of caveolin-1 and SR-B1 in mice with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2013, 12:630-636.
33. Horiuchi S, Unno Y, Usui H, Shikata K, Takaki K, Koito W, Sakamoto Y, Nagai R, Makino K, Sasao A, et al. Pathological roles of advanced glycation end product receptors SR-A and CD36. Ann N Y Acad Sci 2005, 1043:671-675.
34. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov 2011, 1:442-456.
35. Lum DF, Mcquaid KR, Gilbertson VL, Hughes-Fulford M. Coordinate up-regulation of low-density lipoprotein receptor and cyclo-oxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies. Int J Cancer 1999, 83:162-166.
36. Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010, 70:390-400.
37. Dieckmann M, Dietrich MF, Herz J. Lipoprotein receptors-an evolutionarily ancient multifunctional receptor family. Biol Chem 2010, 391:1341-1363.
38. Francke U, Brown MS, Goldstein JL. Assignment of the human gene for the low density lipoprotein receptor to chromosome 19: synteny of a receptor, a ligand, and a genetic disease. Proc Natl Acad Sci U S A 1984, 81:2826-2830.
39. May P, Woldt E, Matz RL, Boucher P. The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann Med 2007, 39:219-228.
40. Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev 2013, 65:121-138.
41. Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD. The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest 2000, 105:521-532.
42. Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J. Reeler/disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 1999, 97:689-701.
43. Dos Santos CR, Domingues G, Matias I, Matos J, Fonseca I, De Almeida JM, Dias S. LDL-cholesterol signaling induces breast cancer proliferation and invasion. Lipids Health Dis 2014, 13:16.
44. Fluiter K, Van Berkel TJ. Scavenger receptor B1 (SR-B1) substrates inhibit the selective uptake of high-density-lipoprotein cholesteryl esters by rat parenchymal liver cells. Biochem J 1997, 326(Pt 2):515-519.
45. Pilon A, Martin G, Bultel-Brienne S, Junquero D, Delhon A, Fruchart JC, Staels B, Clavey V. Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. Biochim Biophys Acta 2003, 1631:218-228.
46. Rigotti A, Acton SL, Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 1995, 270:16221-16224.
47. De La Llera-Moya M, Connelly MA, Drazul D, Klein SM, Favari E, Yancey PG, Williams DL, Rothblat GH. Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. J Lipid Res 2001, 42:1969-1978.
48. Valacchi G, Sticozzi C, Lim Y, Pecorelli A. Scavenger receptor class B type I: a multifunctional receptor. Ann N Y Acad Sci 2011, 1229:E1-E7.
49. Graf GA, Connell PM, Van Der Westhuyzen DR, Smart EJ. The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J Biol Chem 1999, 274:12043-12048.
50. Assmann G, Schulte H, Von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124(suppl):S11-S20.
51. Rodrigueza WV, Thuahnai ST, Temel RE, Lund-Katz S, Phillips MC, Williams DL. Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells. J Biol Chem 1999, 274:20344-20350.
52. Fidge NH. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res 1999, 40:187-201.
53. Provost A, Pequignot M, Salle S, Sainton K, Abitbol M. Gene and protein expression of Srb1 (scavenger receptor class B, type 1) a cell surface HDL receptor of CD36 superfamilly, in the adult rat retina. Invest Ophthalmol Vis Sci 2002, 43:4562.
54. Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuasen RG, Sundfor K, Kristensen GB, Holm R, et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res 2012, 72:5285-5295.
55. Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, et al. Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 2008, 21:665-676.
56. Zheng Y, Liu Y, Jin H, Pan S, Qian Y, Huang C, Zeng Y, Luo Q, Zeng M, Zhang Z. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 2013, 3:477-486.
57. Rensen PC, De Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, Van Berkel TJ. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001, 47:251-276.
58. Rensen PC, De Vrueh RL, Van Berkel TJ. Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1996, 31:131-155.
59. Rensen PC, Van Dijk MC, Havenaar EC, Bijsterbosch MK, Kruijt JK, Van Berkel TJ. Selective liver targeting of antivirals by recombinant chylomicrons-a new therapeutic approach to hepatitis B. Nat Med 1995, 1:221-225.
60. Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, Mckee RT, et al. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 2007, 13:3079-3086.
61. Goncalves RP, Hungria VT, Chiattone CS, Pozzi DB, Maranhao RC. Metabolism of chylomicron-like emulsions in patients with Hodgkin's and with non-Hodgkin's lymphoma. Leuk Res 2003, 27:147-153.
62. Krieger M, Smith LC, Anderson RG, Goldstein JL, Kao YJ, Pownall HJ, Gotto AM Jr, Brown MS. Reconstituted low density lipoprotein: a vehicle for the delivery of hydrophobic fluorescent probes to cells. J Supramol Struct 1979, 10:467-478.
63. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release 2007, 124:163-171.
64. Baillie G, Owens MD, Halbert GW. A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro. J Lipid Res 2002, 43:69-73.
65. Marotta DE, Cao W, Wileyto EP, Li H, Corbin I, Rickter E, Glickson JD, Chance B, Zheng G, Busch TM. Evaluation of bacteriochlorophyll-reconstituted low-density lipoprotein nanoparticles for photodynamic therapy efficacy in vivo. Nanomedicine (Lond) 2011, 6:475-487.
66. Hill ML, Corbin IR, Levitin RB, Cao W, Mainprize JG, Yaffe MJ, Zheng G. In vitro assessment of poly-iodinated triglyceride reconstituted low-density lipoprotein: initial steps toward CT molecular imaging. Acad Radiol 2010, 17:1359-1365.
67. Huntosova V, Buzova D, Petrovajova D, Kasak P, Nadova Z, Jancura D, Sureau F, Miskovsky P. Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells. Int J Pharm 2012, 436:463-471.
68. Allijn IE, Leong W, Tang J, Gianella A, Mieszawska AJ, Fay F, Ma G, Russell S, Callo CB, Gordon RE, et al. Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano 2013, 7:9761-9770.
69. Yang M, Jin H, Chen J, Ding L, Ng KK, Lin Q, Lovell JF, Zhang Z, Zheng G. Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small 2011, 7:568-573.
70. Yang M, Chen J, Cao W, Ding L, Ng KK, Jin H, Zhang Z, Zheng G. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide--phospholipid nanoscaffold. Nanomedicine (Lond) 2011, 6:631-641.
71. Lin Q, Chen J, Jin H, Ng KK, Yang M, Cao W, Ding L, Zhang Z, Zheng G. Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine (Lond) 2012, 7:1813-1825.
72. Gomaraschi M, Calabresi L, Rossoni G, Iametti S, Franceschini G, Stonik JA, Remaley AT. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J Pharmacol Exp Ther 2008, 324:776-783.
73. Marrache S, Dhar S. Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc Natl Acad Sci U S A 2013, 110:9445-9450.
74. Mcconathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 2008, 19:183-188.
75. Mooberry LK, Nair M, Paranjape S, Mcconathy WJ, Lacko AG. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target 2010, 18:53-58.
76. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011, 13:309-319.
77. Sabnis N, Pratap S, Akopova I, Bowman PW, Lacko AG. Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma. Front Pediatr 2013, 1:6.
78. Sabnis N, Nair M, Israel M, Mcconathy WJ, Lacko AG. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomedicine 2012, 7:975-983.
79. Thaxton CS, Daniel WL, Giljohann DA, Thomas AD, Mirkin CA. Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc 2009, 131:1384-1385.
80. Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, Ugolkov AV, Singh AT, Dave SS, Gordon LI, et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci U S A 2013, 110:2511-2516.
81. Mcmahon KM, Mutharasan RK, Tripathy S, Veliceasa D, Bobeica M, Shumaker DK, Luthi AJ, Helfand BT, Ardehali H, Mirkin CA, et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett 2011, 11:1208-1214.
82. Cho KH. Enhanced delivery of rapamycin by V156K-apoA-I high-density lipoprotein inhibits cellular proatherogenic effects and senescence and promotes tissue regeneration. J Gerontol A Biol Sci Med Sci 2011, 66:1274-1285.
83. Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, Zhou X, Liu C, Wang R, Zhang Q. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 2012, 33:8893-8905.
84. Zhang WL, Xiao Y, Liu JP, Wu ZM, Gu X, Xu YM, Lu H. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int J Pharm 2011, 419:314-321.
85. Zhang W, Li J, Liu J, Wu Z, Xu Y, Wang J. Tanshinone IIA-loaded reconstituted high density lipoproteins: Atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits. Pharmazie 2012, 67:324-330.
86. Sigalov AB. Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages. Contrast Media Mol Imaging 2014, epub ahead of print.
87. Khumsupan P, Ramirez R, Khumsupan D, Narayanaswami V. Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Biochim Biophys Acta 2011, 1808:352-359.
88. Ghosh M, Singh AT, Xu W, Sulchek T, Gordon LI, Ryan RO. Curcumin nanodisks: formulation and characterization. Nanomed Nanotechnol Biol Med 2011, 7:162-167.
89. Singh AT, Ghosh M, Forte TM, Ryan RO, Gordon LI. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk Lymphoma 2011, 52:1537-1543.
90. Ghosh M, Ryan RO. ApoE enhances nanodisk-mediated curcumin delivery to glioblastoma multiforme cells. Nanomedicine (Lond) 2013, 9:763-771.
91. Ghosh M, Ren G, Simonsen JB, Ryan RO. Cationic lipid nanodisks as an siRNA delivery vehicle. Biochem Cell Biol 2014, 22:1-6.
92. Ng KK, Lovell JF, Vedadi A, Hajian T, Zheng G. Self-assembled porphyrin nanodiscs with structure-dependent activation for phototherapy and photodiagnostic applications. ACS Nano 2013, 7:3484-3490.
93. Duivenvoorden R, Tang J, Cormode DP, Mieszawska AJ, Izquierdo-Garcia D, Ozcan C, Otten MJ, Zaidi N, Lobatto ME, Van Rijs SM, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 2014, 5:3065.
94. Tauchi Y, Zushida L, Yokota M, Chono S, Sato J, Ito K, Morimoto K. Inhibitory effect of dexamethasone palmitate-low density lipoprotein complex on low density lipoprotein-induced macrophage foam cell formation. Biol Pharm Bull 2000, 23:466-471.
95. Kader A, Pater A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release 2002, 80:29-44.
96. Lin Q, Chen J, Ng KK, Cao W, Zhang Z, Zheng G. Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles. Pharm Res 2013, 31:1438-1449.
97. Jin H, Lovell JF, Chen J, Lin Q, Ding L, Ng KK, Pandey RK, Manoharan M, Zhang Z, Zheng G. Mechanistic insights into LDL nanoparticle-mediated siRNA delivery. Bioconjug Chem 2012, 23:33-41.
98. Vitols S, Soderberg-Reid K, Masquelier M, Sjostrom B, Peterson C. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br J Cancer 1990, 62:724-729.
99. Jori G, Reddi E. The role of lipoproteins in the delivery of tumour-targeting photosensitizers. Int J Biochem 1993, 25:1369-1375.
100. Hammel M, Laggner P, Prassl R. Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system. Chem Phys Lipids 2003, 123:193-207.
101. Li H, Gray BD, Corbin I, Lebherz C, Choi H, Lund-Katz S, Wilson JM, Glickson JD, Zhou R. MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol 2004, 11:1251-1259.
102. De Smidt PC, Van Berkel TJ. Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res 1990, 50:7476-7482.
103. Masquelier M, Vitols S, Peterson C. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res 1986, 46:3842-3847.
104. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007, 59:478-490.
105. Rensen PC, Oosten M, Bilt E, Eck M, Kuiper J, Berkel TJ. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo. J Clin Invest 1997, 99:2438-2445.
106. Saba AB, Ajibade T, Frank S, Kostner G, eds. Role of Lipoproteins in Carcinogenesis and in Chemoprevention. Rijeka, Croatia: Intechopen; 2012.
107. Law SW, Lackner KJ, Hospattankar AV, Anchors JM, Sakaguchi AY, Naylor SL, Brewer HB Jr. Human apolipoprotein B-100: cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2. Proc Natl Acad Sci U S A 1985, 82:8340-8344.
108. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest 1998, 101:1084-1093.
109. Yancey PG, Kawashiri MA, Moore R, Glick JM, Williams DL, Connelly MA, Rader DJ, Rothblat GH. In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. J Lipid Res 2004, 45:337-346.
110. Nykiforuk CL, Shen Y, Murray EW, Boothe JG, Busseuil D, Rheaume E, Tardif JC, Reid A, Moloney MM. Expression and recovery of biologically active recombinant apolipoprotein AI(Milano) from transgenic safflower (Carthamus tinctorius) seeds. Plant Biotechnol J 2011, 9:250-263.
111. Tubb MR, Smith LE, Davidson WS. Purification of recombinant apolipoproteins A-I and A-IV and efficient affinity tag cleavage by tobacco etch virus protease. J Lipid Res 2009, 50:1497-1504.
112. Walsh MT, Atkinson D. Solubilization of low-density lipoprotein with sodium deoxycholate and recombination of apoprotein B with dimyristoylphosphatidylcholine. Biochemistry 1983, 22:3170-3178.
113. Ginsburg GS, Walsh MT, Small DM, Atkinson D. Reassembled plasma low density lipoproteins. Phospholipid-cholesterol ester-apoprotein B complexes. J Biol Chem 1984, 259:6667-6673.
114. Lundberg B. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res 1987, 47:4105-4108.
115. Hirata RD, Hirata MH, Mesquita CH, Cesar TB, Maranhao RC. Effects of apolipoprotein B-100 on the metabolism of a lipid microemulsion model in rats. Biochim Biophys Acta 1999, 1437:53-62.
116. Firestone RA, Pisano JM, Falck JR, Mcphaul MM, Krieger M. Selective delivery of cytotoxic compounds to cells by the LDL pathway. J Med Chem 1984, 27:1037-1043.
117. Kim HR, Kim IK, Bae KH, Lee SH, Lee Y, Park TG. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharm 2008, 5:622-631.
118. Song L, Li H, Sunar U, Chen J, Corbin I, Yodh AG, Zheng G. Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. Int J Nanomedicine 2007, 2:767-774.
119. Corbin IR, Li H, Chen J, Lund-Katz S, Zhou R, Glickson JD, Zheng G. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 2006, 8:488-498.
120. Vogel T, Weisgraber KH, Zeevi MI, Ben-Artzi H, Levanon AZ, Rall SC Jr, Innerarity TL, Hui DY, Taylor JM, Kanner D, et al. Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E. Proc Natl Acad Sci U S A 1985, 82:8696-8700.
121. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A 2005, 102:17757-17762.
122. Bricarello DA, Smilowitz JT, Zivkovic AM, German JB, Parikh AN. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano 2011, 5:42-57.
123. Shiflett AM, Bishop JR, Pahwa A, Hajduk SL. Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem 2005, 280:32578-32585.
124. Bhattacharya P, Grimme S, Ganesh B, Gopisetty A, Sheng JR, Martinez O, Jayarama S, Artinger M, Meriggioli M, Prabhakar BS. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J Virol 2010, 84:361-371.
125. Hu J, Liu H, Wang L. Enhanced delivery of AZT to macrophages via acetylated LDL. J Control Release 2000, 69:327-335.
126. Raygani AV, Rahimi Z, Kharazi H, Tavilani H, Pourmotabbed T. Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neurosci Lett 2006, 408:68-72.
127. Song Q, Huang M, Yao L, Wang X, Gu X, Chen J, Huang J, Hu Q, Kang T, Rong Z, et al. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-β. ACS Nano 2014, 8:2345-2359.
128. Corbin IR, Zheng G. Mimicking nature's nanocarrier: synthetic low-density lipoprotein-like nanoparticles for cancer-drug delivery. Nanomedicine (Lond) 2007, 2:375-380.
129. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 2007, 328:86-94.
130. Lerch PG, Fortsch V, Hodler G, Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang 1996, 71:155-164.
131. Getz GS, Wool GD, Reardon CA. Biological properties of apolipoprotein a-I mimetic peptides. Curr Atheroscler Rep 2010, 12:96-104.
132. Hovingh GK, Bochem AE, Kastelein JJ. Apolipoprotein A-I mimetic peptides. Curr Opin Lipidol 2010, 21:481-486.
133. Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev 2010, 18:141-147.
134. Zhang Z, Cao W, Jin H, Lovell JF, Yang M, Ding L, Chen J, Corbin I, Luo Q, Zheng G. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem Int Ed Engl 2009, 48:9171-9175.
135. Handattu SP, Garber DW, Monroe CE, Van Groen T, Kadish I, Nayyar G, Cao D, Palgunachari MN, Li L, Anantharamaiah GM. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol Dis 2009, 34:525-534.
136. Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) 2013, 8:1509-1528.
137. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013, 8:102.
138. Kshirsagar NA, Pandya SK, Kirodian GB, Sanath S. Liposomal drug delivery system from laboratory to clinic. J Postgrad Med 2005, 51(suppl 1):S5-S15.
139. Sen K, Mandal M. Second generation liposomal cancer therapeutics: transition from laboratory to clinic. Int J Pharm 2013, 448:28-43.
140. Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL, Chan WC, Cao W, Wang LV, Zheng G. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater 2011, 10:324-332.
141. Huynh E, Zheng G. Porphysome nanotechnology: a paradigm shift in lipid-based supramolecular structures. Nano Today 2014, 9:212-222.